Laboratory price list

The package provides information on the state of the male body's haematopoietic system, sex hormone levels, carbohydrate, protein, lipid and fat metabolism, and liver, pancreas, muscle and kidney function. Examine the function and regulation of thyroid hormones. Measures levels of essential ions and vitamin D, markers of possible wasting. The package also includes a urine general and sediment test.

• Carbohydrate metabolism: glucose (GLU, fasting), insulin (fasting)
• Liver function: direct bilirubin (D-Bil), total bilirubin (T-Bil), gamma GT (GGT), aspartate aminotransferase (GOT or AST), alanine aminotransferase (GPT or ALT)
• Lipid, fat metabolism: cholesterol (KOL), LDL cholesterol (LDL), HDL cholesterol (HDL), triglycerides (TG)
• Water: urea (KARB, Urea, N, BUN), creatinine/ EGFR-el (KRE), uric acid (UA)
• Ion Background: iron (Fe), potassium (K), sodium (Na), phosphorus (P), chloride (Cl), calcium (Ca), magnesium (Mg)
• Protein metabolism: albumin (ALB), total protein (TP)
• Inflammation factors: alkaline phosphatase (ALP), C-reactive protein (ultrasensitive, CRP)
• Thyroid function: triiodothyronine free fraction (FT3), thyroxine (tetra-iodothyronine) free fraction (FT4)
• Regulating thyroid hormones: thyroid stimulating hormone (TSH)
• Pancreas function: alpha-amylase (AMY), insulin (fasting)
• Sex hormones: follicle stimulating hormone (FSH), luteinising hormone (LH), sex hormone binding protein (SHBG), testosterone, dehydro-epiandrosterone sulphate (DHEA-s)
• Muscle metabolism: creatine kinase (CK)
• How the haematopoietic system works: iron (Fe), transferrin (Trf), ferritin (FERR)
• Blood clotting: activated partial thromboplastin time (APTI), prothrombin+INR (PT+ INR)
• Vitamins: Vitamin D3 (D3)
• Vvascular image 22 parametersr, Blood counts: white blood cell (WBC), red blood cell (RBC), haemoglobin (HGB), haematocrit (HCT), red blood cell volume (MCV), red blood cell haemoglobin concentration (MCH), mean cell haemoglobin concentration (MCHC). Quality blood count parameters (both in % and absolute value): neutrophil granulocyte (NEUT), lymphocyte (LYMPH), monocyte (MONO), eosinophil granulocyte (EOS), basophil granulocyte (BASO), large immature cells (LUC). Trombocita parameters: platelet (PLT), mean platelet volume (MPV), platelet distribution curve width (PDW), platelet crit (PCT).
• Reticulocyte parameters: reticulocita (% RETIC), reticulocita (abs RETIC)
• Urine sediment test: red blood cell, white blood cell, white blood cell conglomerate, bacterium, fungus, squamous cell carcinoma, squamous cell non carcinoma, crystal, hyaline cylinder, pathological cylinder, sperm, sputum
• General urinalysis: glucose, protein, blood, bilirubin, urobilinogen, pH, ketone, nitrite, white blood cell, specific gravity, colour, turbidity (protein/creatinine ratio (calculated).

The Men's Health Assessment Plus package provides information on the status of the male body's haematopoietic system, sex hormone levels, carbohydrate, protein, lipid and fat metabolism, and liver, pancreas, muscle and kidney function. Examine the function and regulation of thyroid hormones. Measures levels of essential ions and vitamins, markers of possible wasting. The package also includes a tumour marker test (PSA), urine general and sediment tests.

• Carbohydrate metabolism: glucose (GLU, fasting), insulin (fasting)
• Liver function: direct bilirubin (D-Bil), total bilirubin (T-Bil), gamma GT (GGT), aspartate aminotransferase (GOT or AST), alanine aminotransferase (GPT or ALT)
• Lipid, fat metabolism: cholesterol (KOL), LDL cholesterol (LDL), HDL cholesterol (HDL), triglycerides (TG)
• Water: urea (KARB, Urea, N, BUN), creatinine/ EGFR-el (KRE), uric acid (UA)
• Ion Background: iron (Fe), potassium (K), sodium (Na), phosphorus (P), chloride (Cl), calcium (Ca), magnesium (Mg)
• Protein metabolism: albumin (ALB), total protein (TP)
• Inflammation factors: alkaline phosphatase (ALP), C-reactive protein (ultrasensitive, CRP)
• Thyroid function: triiodothyronine free fraction (FT3), thyroxine (tetra-iodothyronine) free fraction (FT4)
• Regulating thyroid hormones: thyroid stimulating hormone (TSH)
• Pancreas function: alpha-amylase (AMY), insulin (fasting)
• Sex hormones: follicle stimulating hormone (FSH), luteinising hormone (LH), sex hormone binding protein (SHBG), testosterone, androstenedione, dehydro-epiandrosterone sulphate (DHEA)
• Muscle metabolism: creatine kinase (CK), creatine kinase-MB (CK-MB)
• How the haematopoietic system works: iron (Fe), transferrin (Trf), ferritin (FERR)
• Tumour markers: prostate specific antigen (PSA)
• Blood clotting: activated partial thromboplastin time (APTI), prothrombin+INR (PT+ INR)
• Vitamins: Vitamin D3 (D3), vitamin B12 (B12, cobalamin)
• Vvascular image 22 parametersr: Blood counts: white blood cell (WBC), red blood cell (RBC), haemoglobin (HGB), haematocrit (HCT), red blood cell volume (MCV), red blood cell haemoglobin concentration (MCH), mean cell haemoglobin concentration (MCHC). Quality blood count parameters (both in % and absolute value): neutrophil granulocyte (NEUT), lymphocyte (LYMPH), monocyte (MONO), eosinophil granulocyte (EOS), basophil granulocyte (BASO), large immature cells (LUC). Trombocita parameters: platelet (PLT), mean platelet volume (MPV), platelet distribution curve width (PDW), platelet crit (PCT).
• Reticulocyte parameters: reticulocita (% RETIC), reticulocita (abs RETIC)
• Urine sediment test: red blood cell, white blood cell, white blood cell conglomerate, bacterium, fungus, squamous cell carcinoma, squamous cell non carcinoma, crystal, hyaline cylinder, pathological cylinder, sperm, sputum
• General urinalysis: glucose, protein, blood, bilirubin, urobilinogen, pH, ketone, nitrite, white blood cell, specific gravity, colour, turbidity (protein/creatinine ratio (calculated)

Hair loss can be triggered by a number of factors. In addition to genetic causes, there are often hormonal changes (testosterone/estrogen ratio, thyroid disorders), inflammation, vitamin deficiencies, infections, skin diseases, chemical effects, poisoning, radiation and burns, prolonged stress, temporary weakening of the immune system, organ diseases, drug effects. It can also be triggered by a decrease in the levels of certain ions (iron, zinc, calcium).

• Carbohydrate metabolism: glucose (GLU, fasting glucose), insulin
• Liver function: direct bilirubin (D-Bil), total bilirubin (T-Bil), gamma GT (GGT), aspartate aminotransferase (GOT or AST), alanine aminotransferase (GPT or ALT)
• Lipid, fat metabolism: cholesterol (KOL), LDL cholesterol (LDL), HDL cholesterol (HDL), triglycerides (TG)
• Water: urea (KARB, Urea, N, BUN), creatinine/ EGFR-el (KRE), uric acid (UA)
• Ion Background: iron (Fe), magnesium (Mg), zinc (Zn)
• Protein metabolism: albumin (ALB), total protein (TP)
• Inflammation factors: alkaline phosphatase (ALP), C-reactive protein (ultrasensitive, CRP)
• Vitamins: Vitamin B12 (B12, cobalamin), folic acid, vitamin D3 (D3)
• Pancreas: insulin
• Sex hormones: follicle stimulating hormone (FSH), luteinising hormone (LH), sex hormone binding protein (SHBG), testosterone, dehydro-epiandrosterone sulphate (DHEA-s)
• Thyroid function: anti-thyroid peroxidase antibody (anti-TPO)
• Regulating thyroid hormones: thyroid stimulating hormone (TSH)
• Infection serology: anti-streptolysin "O" streptococcus infection (ASO, ASLO)
• Autoimmune investigation: antinuclear antibody screen (ANA screen), extractable nuclear antigen (ENA) screen
• How the haematopoietic system works: iron (Fe), transferrin (Trf), ferritin (FERR)
• Vvascular image 22 parametersr: Blood counts: white blood cell (WBC), red blood cell (RBC), haemoglobin (HGB), haematocrit (HCT), red blood cell volume (MCV), red blood cell haemoglobin concentration (MCH), mean cell haemoglobin concentration (MCHC). Quality blood count parameters (both in % and absolute value): neutrophil granulocyte (NEUT), lymphocyte (LYMH), monocyte (MONO), eosinophil granulocyte (EOS), basophil granulocyte (BASO), large immature cells (LUC). Trombocita parameters: platelet (PLT), mean platelet volume (MPV), platelet distribution curve width (PDW), platelet crit (PCT).

Our men's tumour marker kit can help you find out about the types of tumours that most commonly affect men. The package includes laboratory measurements of tumour markers that are elevated in liver, stomach, colon, lung, prostate and testicular lesions.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
When liver cells are formed, alpha-feto-protein (AFP) is produced. Levels are elevated in liver, ovarian and testicular cancer.
Among the test parameters, cancer antigen 125 II (CA-125) may indicate ovarian, cancer antigen 19-9 (CA-19-9) may indicate pancreatic, bile duct, colon, lung, gallbladder, and cancer antigen 15-3 (CA-15-3) may indicate breast, colon, lung tumours.
The main indication for CA 72-4 is the treatment of gastric cancer patients and the monitoring of disease progression.
β-2-Microglobulin (B2M) is produced by the body's immune system (B lymphocytes) or by tumour cells. It can also be used to diagnose certain kidney diseases (glomerular dysfunction). Levels are elevated in tumours affecting the haematopoietic system (multiple myeloma, lymphoma, B-cell chronic lymphocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma) and testis.
The carcino-embryonic antigen (CEA) is produced by embryonic and tumour cells. Levels are elevated in gastrointestinal tumours. Its value is also high in breast, lung, liver, pancreatic and ovarian cancers.
For non-small cell lung cancer (mainly squamous cell and large cell carcinoma subtypes), CYFRA 21-1 is considered the most suitable biomarker.
Human Chorionic Gonadotropin (HCG, free B-HCG) is produced in the cells of the placenta in women and plays a role in maintaining the corpus luteum during pregnancy.
In men, an elevated value may also indicate a pancreatic or testicular tumour.
Lactoferrin is an iron-binding protein that is also present in neutrophil granulocytes involved in the inflammatory immune response. Thus, its levels are measured in relation to the inflammatory processes in gastrointestinal diseases. Levels may also be elevated in colorectal tumours.
Calprotectin is a calcium-, zinc- and manganese-binding protein produced by neutrophil granulocytes and monocytes. Its levels may also be elevated in colorectal tumours.
Prostate-specific antigen (PSA) is produced by the epithelial cells of the prostate gland. PSA levels higher than 10 ng/ml are likely to indicate the presence of prostate cancer. For screening, the free PSA fraction and the total PSA/free PSA ratio are evaluated. Free PSA levels are lower in prostate cancer and higher in prostate enlargement.
Annual PSA screening is recommended for people over 45 years of age, as early diagnosis of malignant prostate cancer is curable.
The neuron-specific enolase (NSE) measurement is mainly used to monitor the effectiveness of therapy and to assess changes in the condition of patients with tumours, especially small-cell lung cancer and neuroblastoma.
The measurement of S-100 protein can be used to support the treatment of patients with malignant melanoma and to support the treatment of patients who have suffered a brain injury (traumatic brain injury or stroke).
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.

These tumour markers are not specific!
CA 19-9 levels may also be elevated in biliary cancer, pancreatitis, cystic fibrosis and liver disease.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis).

CEA levels may be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Elevated CYFRA 21-1 levels have also been described in non-malignant diseases (e.g. pneumonia, sepsis) and abnormal kidney function.
High AFP values can also be obtained in cases of hepatitis, cirrhosis, hepatitis.
β-2-Microglobulin (B2M) levels can also be elevated in renal inflammation, autoimmune diseases (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjörgen syndrome (SjS)), Crohn's disease, and infections (cytomegalovirus (CMV), nonA-nonB hepatitis, mononucleosis infectiosa, HIV).
PSA levels can also rise in benign prostatic hyperplasia.
Elevated NSE levels may also occur in malignant neuroendocrine diseases and in many other tumour diseases and clinical pathologies.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum test): alpha-feto-protein (AFP), β-2-microglobulin (B2M), cancer antigen 19-9 (CA-19-9), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA), chromogranin A (CgA), Cyfra-21-1, free β human chorionic gonadotropin (free β-HCG), prostate specific antigen (PSA), prostate specific antigen free (PSA free), neuron-specific enolase (NSE), S-100 protein

Our male sex tumour marker kit can help you find out about the occurrence of tumours that most commonly affect men. The package includes laboratory measurements of tumour markers for liver, prostate, testicular lesions and elevated tumour markers for neuroendocrine tumours.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) is produced. Levels are elevated in liver, ovarian and testicular cancer.
A β-2-microglobulin (B2M) produced by the body's immune system (B lymphocytes) or by tumour cells. It can also be used to diagnose certain kidney diseases (glomerular dysfunction). Levels are elevated in haematopoietic system (multiple myeloma, lymphoma, B-cell chronic lymphocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma) and in tumours affecting the testis.
A Human Chorio-Gonadotropin (HCG, free B-HCG) in men may also indicate a pancreatic or testicular tumour.
A prostate specific antigen (PSA) produced by the epithelial cells of the prostate gland. A PSA level higher than 10 ng/ml indicates the presence of prostate cancer. At screening, the free PSA fraction and the total PSA/free PSA ratio are assessed. Free PSA levels are lower in prostate cancer and higher in prostate enlargement.
Annual PSA screening is recommended for people over 45 years of age, as early diagnosis of malignant prostate cancer is curable.
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.

These tumour markers are not specific!
High AFP values can also be obtained in cases of hepatitis, cirrhosis, hepatitis.
β-2-Microglobulin (B2M) levels can also be elevated in renal inflammation, autoimmune diseases (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjörgen syndrome (SjS)), Crohn's disease, and infections (cytomegalovirus (CMV), nonA-nonB hepatitis, mononucleosis infectiosa, HIV).
PSA levels can also rise in benign prostatic hyperplasia.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum tests): alpha-feto-protein (AFP), β-2-microglobulin (B2M), free β-human chorionic gonadotropin (free β-HCG), chromogranin A (CgA), prostate-specific antigen (PSA), prostate-specific antigen free (PSA free)

Our gastrointestinal tumour marker package includes laboratory measurement of elevated tumour markers in liver, ovarian, colorectal and pancreatic lesions.

Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) Produced by. Levels are elevated in liver and ovarian cancer.
A cancer antigen 19-9 (CA-19-9) may indicate the development of tumours of the pancreas, bile ducts, colon, lungs, gall bladder.
A CA 72-4 is mainly indicated for the treatment of gastric and ovarian cancer patients and to monitor the progression of the disease.
A carcino-embryonic antigen (CEA) produced by embryonic and tumour cells. Levels are elevated in gastrointestinal tumours. Its value is also high in breast, lung, liver, pancreatic and ovarian cancers.
Cancer antigen 242 (CA-242) a tumour marker for colorectal cancer and pancreatic tumours.
A lactoferrin an iron-binding protein that is also present in neutrophil granulocytes involved in the inflammatory immune response. Thus, its levels are measured in relation to the inflammatory processes in gastrointestinal diseases. Levels may also be elevated in colorectal tumours.
A calprotectin calcium-, zinc- and manganese-binding protein produced by neutrophil granulocytes and monocytes. Levels may also be elevated in colorectal tumours.

These tumour markers are not specific!
High AFP values can also be obtained in cases of hepatitis, cirrhosis and hepatitis.
CA 19-9 levels may also be elevated in biliary cancer, pancreatitis, cystic fibrosis and liver disease.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels may be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.

• Tumour markers (serum tests): alpha-feto-protein (AFP), cancer antigen 19-9 (CA-19-9), cancer antigen 242 (CA-242), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA)
• Stool tests: stool blood test, lactoferrin, calprotectin

Our lung tumour marker package includes laboratory measurement of elevated tumour markers in lung lesions.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
For non-small cell lung cancer, the CA 72-4 and the CYFRA 21-1 is considered the most suitable biomarker.

A carcino-embryonic antigen (CEA) produced by embryonic and tumour cells. Levels may also be elevated in lung tumours.
A neuron-specific enolase (NSE) measurement can be used to monitor the effectiveness of therapy and to assess changes in the condition of patients with tumours, particularly small-cell lung cancer and neuroblastoma.

These tumour markers are not specific!
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels may be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Elevated CYFRA 21-1 levels have also been described in non-malignant diseases (e.g. pneumonia, sepsis) and abnormal kidney function.
Elevated NSE levels may also occur in malignant neuroendocrine diseases and in many other tumour diseases and clinical pathologies.

• Tumour markers (serum tests): cancer antigen 72-4 (CA-72-4), carcinoembryonic antigen (CEA), Cyfra-21-1, neuron-specific enolase (NSE)